RegulationApprovals September 4, 2018 Sanofi gets EC approval for blood-clotting disorder drug Cablivi By PBR Staff Writer Cablivi is claimed to be the first therapeutic specifically developed to treat aTTP, a rare blood-clotting disorder. The approval was based on data from the phase II Titan
RegulationApprovals August 31, 2018 Merck secures FDA approval for two HIV drugs By PBR Staff Writer Delstrigo is a once-daily fixed-dose combination tablet of doravirine (100mg), lamivudine (3TC, 300mg) and tenofovir disoproxil fumarate (TDF, 300mg). Pifeltro (doravirine, 100mg) is a new non-nucleoside reverse transcriptase
Drug DiscoveryResearch & Development August 30, 2018 KaNDy Therapeutics raises £25m to advance non-hormonal drug candidate By PBR Staff Writer KaNDy is focused on optimizing the potential of NT-814 as a non-hormonal treatment for common, chronic debilitating female sex-hormone associated conditions. The funding came from new US investor
Clinical TrialsHuman Trials August 28, 2018 MXC gets approval for phase 2 trial of marijuana-based CogniCann in dementia By PBR Staff Writer CogniCann is one of MXC’s medical cannabis pharmaceutical products with a THC:CBD ratio specifically formulated to treat key Dementia symptoms and enhance specific cognitive functions. The approval was
Drug DiscoveryResearch & Development August 27, 2018 JWP out-licenses atopic dermatitis drug JW1601 to LEO in $402m deal By vbandhakavi The agreement will not include South Korea where JWP will retain its exclusivity over the JW1601 drug, which was developed by one of its affiliates – C&C Research
RegulationApprovals August 23, 2018 FDA approves Dompé’s Oxervate to treat neurotrophic keratitis By PBR Staff Writer NK is a rare and progressive eye disease, which may result in corneal scarring and vision loss. The FDA has approved Oxervate eye drops for use in adults
Clinical TrialsHuman Trials August 22, 2018 Rexahn partners with Merck on combo study in TNBC By PBR Staff Writer The partnership will assess Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy in a phase 2 study in patients with metastatic triple negative breast cancer (TNBC). The trial has been